Study nudges Abbott's Duodopa towards US approval but Ph III pardoprunox is dumped
This article was originally published in Scrip
Executive Summary
Abbott's announcement of positive efficacy results yesterday indicate that one of a brace of Phase III Parkinson's disease drugs it acquired with Solvay back in 2010 is on track for a US filing this year, but it the company has quietly abandoned development of the other one, pardoprunox.